Fetal Demise in PCOS Patients

Primary Risk Factors

Women with PCOS face substantially elevated risks of pregnancy complications, including a 2-fold higher risk of stillbirth, a 2-2.6 times higher rate of placental abruption, 1.35-3.55 times more common fetal distress, and 1.5-1.7 times more frequent small for gestational age, indicating chronic placental insufficiency 1

The American Diabetes Association recommends discontinuing metformin by the end of the first trimester when used solely for PCOS and ovulation induction, as it does not prevent pregnancy complications that lead to fetal demise and may expose the fetus to concerning long-term metabolic effects 2, 3, 4, 5, 6, 7, 8
Metformin is contraindicated in women with hypertension or preeclampsia, as it may worsen growth restriction or acidosis with placental insufficiency 2, 5, 7, 8
Metformin does not prevent gestational diabetes in high-risk women with PCOS, obesity, or insulin resistance 6, 8

Metformin-exposed fetuses have larger head circumference at birth, particularly in offspring of overweight mothers, and may experience smaller neonatal size with accelerated postnatal growth leading to higher childhood BMI 2, 3, 5

The American Diabetes Association explicitly states there is no evidence-based need to continue metformin in PCOS patients once pregnancy is confirmed unless the patient has type 2 diabetes requiring ongoing treatment 4, 7